After withdrawal in Europe market, Indian drug regulator wan
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The Indian drug regulator, just like the USFDA, has advised its patients who are put under BVS to report any cardiac symptoms such as irregular heartbeats, chest pain or shortness of breath to seek medical help. This comes a week after US drugmaker Abbott restricted the sale of its bioresorbable stents (BVS) in the European market.

Based on the three year clinical data analysis from ABSORB 11, it has been observed that there is an over elevated rate of major adverse cardiac events, specifically myocardial infarction and scaffold thrombosis.

The decision comes after Abbott revealed in March that an increased rate of major adverse cardiac events, specifically myocardial infarction and scaffold thrombosis, has been observed in patients receiving the BVS, when compared to patients treated with the approved (and widely used) drug-eluting stent.

http://economictimes.indiatimes.com/industry/healthcare/biotech/abbott-asks-indian-patients-to-report-adverse-effects-of-bvs/articleshow/58117914.cms
Preview
Like
Comment
Share